Author: Acumen Research and Consulting

As per Acumen Research & Consulting findings, the global Human Chorionic Gonadotropin Market reached a valuation of USD 812.7 Million in 2022. It is anticipated to witness substantial growth, with an estimated value of USD 1,654.8 Million by 2032, reflecting a steady CAGR of 7.5% over the forecast period

Human chorionic gonadotropin (hCG) is a hormone produced by the placenta following zygote implantation in the uterus. Structurally, hCG is similar to luteinizing hormone (LH), a pituitary hormone responsible for ovarian stimulation during normal ovulation. During fertility treatment, hCG is administered via injection to stimulate the final maturation and release of egg cells during ovulation. Additionally, hCG serves various purposes in both men and women. In women, it is used alongside fertility drugs to enhance the chances of pregnancy. In men and adolescent boys, hCG stimulates androgen and sperm production. It can also be utilized in males with cryptorchidism, a birth defect of the testes.

The increased availability of infertility treatment and services, as well as increased awareness about therapies for infertility issues is driving up demand for human chorionic gonadotropin (hCG) industry in developing nations. The rising prevalence of hypogonadism-related illnesses in men, particularly in elderly men, is a primary factor of the human chorionic gonadotropin (hCG) market. Efforts by global health organizations and non-governmental organizations to improve the sexual and reproductive health of people in developing countries are also increasing demand for the market. Furthermore, sedentary lifestyles and stress in personal and professional lives have contributed to fertility issues. Women in cities are more likely to seek medical attention for female-specific ailments that have a negative impact on their quality of life. Another factor driving the growth of the market for human chorionic gonadotropin (hCG) is the increase in the number of elderly women. However, the FDA has issued certain warnings about the risks of using human chorionic gonadotropin as a therapy, which is expected to limit the growth of the human chorionic gonadotropin market in the coming years.

Human Chorionic Gonadotropin Market Statistics

• The global human chorionic gonadotropin market is projected to reach USD 812.7 million in 2022, with a 7.5% CAGR from 2023 to 2032
• North America led in 2022, holding over 38% market share
• The Asia-Pacific region is poised for growth, with a CAGR exceeding 8% from 2023 to 2032
• Female infertility treatment dominated the therapeutic area segment in 2022, representing over 42% of the market
• Hospital pharmacies distribution channel contributed around US$ 455.1 million in 2022
• Growing emphasis on early pregnancy detection is a significant trend in human chorionic gonadotropin (hGC) market

Request for a sample of this premium research report@ https://www.acumenresearchandconsulting.com/request-sample/2873

Human Chorionic Gonadotropin Market Dynamics

The Significant Increase in Infertility Issues among Men and Women is Fueling the Human Chorionic Gonadotropin Market Value

Lifestyle changes, delayed family planning, environmental variables, and underlying health concerns are all contributing to the large increase in infertility issues among men and women. Stress, obesity, smoking, and alcohol intake can all have a detrimental influence on fertility in both men and women. Delayed family planning, with more couples attempting to conceive later in life, can raise the chance of infertility. Environmental variables such as pollution and toxin exposure can also play a role. Infertility can also be exacerbated by underlying health diseases such as polycystic ovarian syndrome (PCOS), endometriosis, and male reproductive abnormalities. All of these causes have contributed to an increase in infertility among both sexes.

Infertility is a global health issue that affects a significant portion of people of reproductive age. According to the World Health Organization (WHO), more than 48 million married couples (15%) and 186 million individuals worldwide grapple with infertility. In infertility treatments, such as IVF, hCG shots are often used in conjunction with other medications to stimulate ovulation in women. In females, hCG is employed to enhance ovulation and promote final follicle maturation, while also providing luteal phase support during infertility treatment.

Men are directly responsible for 20-30% of fertility problems and contribute to 50% of all infertility cases. In males, hCG can be used to boost testosterone levels, a function performed by granulosa cells, in cases of hormonal imbalance and male hypogonadism.

Rise in popularity of fertility tourism Will Generate Surplus Worldwide Human Chorionic Gonadotropin Market Opportunities

The surge in fertility tourism is opening up new prospects in the healthcare and tourist industries. Individuals or couples travelling overseas for fertility treatments and assisted reproductive technologies are examples of fertility tourism. This tendency is influenced by a variety of things.

For starters, cost reductions are a key motivator. Due to different healthcare expenses and insurance coverage, fertility treatments might be costly in various countries. Travelling to destination nations frequently allows people to receive equivalent treatments at a reduced cost, potentially saving them a lot of money.

Second, having access to sophisticated procedures is essential. Some nations provide cutting-edge fertility therapies that individuals' native countries may not have easy access to. This draws people looking for cutting-edge reproductive methods, which contribute to the expansion of fertility tourism.

Overall, reproductive tourism is on the rise, providing individuals and couples seeking fertility solutions with cost-effective alternatives and access to modern therapies.

Human Chorionic Gonadotropin Market Segmentation

The global human chorionic gonadotropin market has been categorized into technology, therapeutic area, distribution channel, end-user, and region

• The technology segment of the market is divided into two categories: natural source extraction and recombinant technology
• The therapeutic area segment is categorized into female infertility treatment, male hypogonadism, oligospermia treatment, and others
• The distribution channel segment encompasses hospital pharmacies, retail pharmacies, and online pharmacies
• The human chorionic gonadotropin market serves several end-users, including fertility clinics, research institutions, and others
• Geographically, the market is segmented into five regions: North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa (MEA)

Human Chorionic Gonadotropin Market Share

The human chorionic gonadotropin (hGC) market forecast indicates that the natural source extraction technology will maintain the largest market share from 2023 to 2032.

Female infertility treatment, by therapeutic area held a significant market share in 2022, and this trend is expected to continue in the future.

In the coming years, hospital pharmacies are projected to lead the market, while online pharmacies are anticipated to gain significant traction from 2023 to 2032.

In terms of human chorionic gonadotropin hGC market analysis, the fertility clinics currently commands the largest market share, with the research institutions industry expected to gain substantial momentum in the coming years.

Human Chorionic Gonadotropin Market Regional Outlook

North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa are the regional classifications for the global human chorionic gonadotropin (hGC) market. According to the analysis, the percentage of infertile men ranged from 12 percent to 25 percent, with reproductive difficulties due to male causes ranging from 20 percent to 70 percent. The African and European regions reported the highest rates of infertility. Additionally, rates of sexual dysfunction in males and females were observed to be 4.5-6% in North America, 8-12% in Central & Eastern Europe, and 9% in Australia, as reported by various sources. In 2020, North America held the largest market share, which is expected to continue during the forecast period. Furthermore, the rising prevalence of conditions such as polycystic ovary syndrome, endometriosis, hormonal imbalance, and other disorders is anticipated to drive the North American hCG market.

Human Chorionic Gonadotropin Market Players

Some prominent human chorionic gonadotropin companies covered in the industry include Bristol Myers Squibb Company, Cigna, Merck & Co., Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd, Ferring Pharmaceuticals Inc, Scripps Laboratories, Lee BioSolutions Inc., Sanzyme, and LUPIN.

Click here to buy the Premium Market Research report https://www.acumenresearchandconsulting.com/buy-now/0/2873

Receive our personalized services and customization by clicking here https://www.acumenresearchandconsulting.com/request-customization/2873

Mr. Frank Wilson

Acumen Research and Consulting

USA: +13474743864

India: +918983225533

E-mail: sales@acumenresearchandconsulting.com